Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
12.37
+1.08 (9.57%)
At close: Nov 9, 2026, 4:00 PM EST
12.42
+0.05 (0.40%)
Pre-market: Nov 10, 2026, 7:01 AM EST
Ginkgo Bioworks Holdings Revenue
Ginkgo Bioworks Holdings had revenue of $27.71M in the quarter ending September 30, 2026, a decrease of -5.68%. In the year 2025, Ginkgo Bioworks Holdings had annual revenue of $170.16M, down -25.06%. That makes Ginkgo Bioworks Holdings the 20,707th largest company in the world by revenue and 3,128th in the United States.
Revenue (ttm)
$170.16M
Revenue Growth
-25.06%
P/S Ratio
6.37
Revenue / Employee
$269,592
Employees
485
Market Cap
833.00M
Revenue by Segment
- Cell Engineering 132.75M 78.0%
- Biosecurity Service 37.41M 22.0%
Fiscal year ended Dec 31, 2025 See the full Ginkgo Bioworks Holdings breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.16M | -56.89M | -25.06% |
| Dec 31, 2024 | 227.04M | -24.41M | -9.71% |
| Dec 31, 2023 | 251.46M | -226.25M | -47.36% |
| Dec 31, 2022 | 477.71M | 163.87M | 52.21% |
| Dec 31, 2021 | 313.84M | 237.18M | 309.40% |
| Dec 31, 2020 | 76.66M | 22.47M | 41.48% |
| Dec 31, 2019 | 54.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 468.22M |
| Rigel Pharmaceuticals | 288.21M |
| Arbutus Biopharma | 181.72M |
| OmniAb | 40.21M |
| Lexicon Pharmaceuticals | 38.54M |
| Alumis | 7.40M |
DNA News
- 4 days ago - Ginkgo Bioworks affirms 2026 cash burn target ($150M)-($125M) - TheFly
- 4 days ago - Ginkgo Bioworks Holdings Earnings Call Transcript: Q3 2026 - Transcripts
- 4 days ago - Ginkgo Bioworks Holdings Earnings release: Q3 2026 - Filings
- 4 days ago - Ginkgo Bioworks Holdings Slides: Q3 2026 - Filings
- 4 days ago - Ginkgo Bioworks Holdings Quarterly report: Q3 2026 - Filings
- 4 days ago - Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo - Business Wire
- 27 days ago - Ginkgo Bioworks price target raised to $11 from $9 at TD Cowen - TheFly
- 4 weeks ago - Ginkgo Bioworks to provide autonomous lab access to NSF X-Labs researchers - TheFly